All Stories

  1. Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

    Article • Patient Preference and Adherence, October 2019, Taylor & Francis

    Dr MITSUKUNI SUENGA, Takeshi Aoyama

  2. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

    Article • Cancer Management and Research, June 2019, Dove Medical Press

    Dr MITSUKUNI SUENGA

  3. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

    Article • OncoTargets and Therapy, November 2018, Dove Medical Press

    Dr MITSUKUNI SUENGA

  4. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

    Article • OncoTargets and Therapy, November 2015, Dove Medical Press

    Dr MITSUKUNI SUENGA

  5. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

    Article • OncoTargets and Therapy, August 2015, Dove Medical Press

    Dr MITSUKUNI SUENGA

  6. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

    Article • Drug Design Development and Therapy, June 2015, Dove Medical Press

    Dr MITSUKUNI SUENGA

  7. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

    Article • OncoTargets and Therapy, May 2015, Dove Medical Press

    Dr MITSUKUNI SUENGA

  8. Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

    Article • Patient Preference and Adherence, April 2015, Taylor & Francis

    Dr MITSUKUNI SUENGA

  9. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

    Article • OncoTargets and Therapy, March 2015, Taylor & Francis

    Dr MITSUKUNI SUENGA

  10. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

    Article • Drug Design Development and Therapy, March 2015, Taylor & Francis

    Dr MITSUKUNI SUENGA

  11. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

    Article • OncoTargets and Therapy, January 2015, Taylor & Francis

    Dr MITSUKUNI SUENGA